Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy

Hematological OncologyVolume 42, Issue 1 e3243 LETTER TO THE EDITOR Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy Hazim S. Ababneh, Hazim S. Ababneh orcid.org/0000-0002-0393-9852 Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USASearch for more papers by this authorMatthew J. Frigault, Matthew J. Frigault Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USASearch for more papers by this authorAndrea K. Ng, Andrea K. Ng Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USASearch for more papers by this authorChirayu G. Patel, Corresponding Author Chirayu G. Patel [email protected] Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA Correspondence Chirayu G. Patel, MGH Radiation Oncology, 55 Fruit St Cox 3, Boston, MA 02114, USA. Email: [email protected]Search for more papers by this author Hazim S. Ababneh, Hazim S. Ababneh orcid.org/0000-0002-0393-9852 Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USASearch for more papers by this authorMatthew J. Frigault, Matthew J. Frigault Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USASearch for more papers by this authorAndrea K. Ng, Andrea K. Ng Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USASearch for more papers by this authorChirayu G. Patel, Corresponding Author Chirayu G. Patel [email protected] Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA Correspondence Chirayu G. Patel, MGH Radiation Oncology, 55 Fruit St Cox 3, Boston, MA 02114, USA. Email: [email protected]Search for more papers by this author First published: 16 December 2023 https://doi.org/10.1002/hon.3243Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Open Research PEER REVIEW The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.3243. DATA AVAILABILITY STATEMENT The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. REFERENCES 1Akin S, Hosing C, Khouri I, et al. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Adv. 2022; 6(7): 2267-2274. https://doi.org/10.1182/BLOODADVANCES.2021005602 10.1182/bloodadvances.2021005602 CASPubMedWeb of Science®Google Scholar 2Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI. Natural history of cns relapse in patients with aggressive non-hodgkin's lymphoma: a 20-year follow-up analysis of swog 8516-the southwest oncology group. J Clin Oncol. 2009; 27(1): 114-119. https://doi.org/10.1200/JCO.2008.16.8021 10.1200/JCO.2008.16.8021 PubMedWeb of Science®Google Scholar 3El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018; 93: 57-68. https://doi.org/10.1016/j.ejca.2018.01.073 10.1016/j.ejca.2018.01.073 PubMedWeb of Science®Google Scholar 4Ferreri AJM, Doorduijn JK, Re A, et al. MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021; 8(2): e110-e121. https://doi.org/10.1016/S2352-3026(20)30366-5 10.1016/S2352-3026(20)30366-5 CASPubMedWeb of Science®Google Scholar 5Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531-2544. https://doi.org/10.1056/nejmoa1707447 10.1056/NEJMoa1707447 CASPubMedWeb of Science®Google Scholar 6Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1): 45-56. https://doi.org/10.1056/nejmoa1804980 10.1056/NEJMoa1804980 CASPubMedWeb of Science®Google Scholar 7Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254): 839-852. https://doi.org/10.1016/S0140-6736(20)31366-0 10.1016/S0140-6736(20)31366-0 PubMedWeb of Science®Google Scholar 8Frigault MJ, Maus MV, Dietrich J, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019; 134(11): 860-866. https://doi.org/10.1182/BLOOD.2019001694 10.1182/blood.2019001694 CASPubMedWeb of Science®Google Scholar 9Asghar N, Masood A, Dhaliwal A, et al. Chimeric antigen receptor T-cell (CAR T-cell) therapy for primary and secondary central nervous system lymphoma: a systematic Review of literature. Clin Lymphoma Myeloma Leuk. 2023; 23(1): 15-21. https://doi.org/10.1016/j.clml.2022.09.008 10.1016/j.clml.2022.09.008 CASPubMedWeb of Science®Google Scholar 10Cook MR, Dorris CS, Makambi KH, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023; 7(1): 32-39. https://doi.org/10.1182/BLOODADVANCES.2022008525 10.1182/bloodadvances.2022008525 CASPubMedWeb of Science®Google Scholar 11Milgrom SA, Pinnix CC, Chi TL, et al. Radiation therapy as an effective salvage strategy for secondary CNS lymphoma. Int J Radiat Oncol Biol Phys. 2018; 100(5): 1146-1154. https://doi.org/10.1016/j.ijrobp.2018.01.003 10.1016/j.ijrobp.2018.01.003 PubMedWeb of Science®Google Scholar 12Walburn T, Grover NS, Shen CJ, et al. Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma. Leuk Lymphoma. 2020; 62(1): 68-75. https://doi.org/10.1080/10428194.2020.1821014 10.1080/10428194.2020.1821014 PubMedWeb of Science®Google Scholar 13Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021; 5(24): 5626-5630. https://doi.org/10.1182/BLOODADVANCES.2021005292 10.1182/bloodadvances.2021005292 CASPubMedWeb of Science®Google Scholar 14Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2): 188-195. https://doi.org/10.1182/blood-2014-05-552729 10.1182/blood-2014-05-552729 CASPubMedWeb of Science®Google Scholar 15Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4): 625-638. https://doi.org/10.1016/j.bbmt.2018.12.758 10.1016/j.bbmt.2018.12.758 CASPubMedWeb of Science®Google Scholar 16Cox JD, Stetz JA, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5): 1341-1346. https://doi.org/10.1016/0360-3016(95)00060-C 10.1016/0360-3016(95)00060-C CASPubMedWeb of Science®Google Scholar 17Ababneh HS, Abramson JS, Johnson PC, Patel CG. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. Radiother Oncol. 2022; 175: 65-72. https://doi.org/10.1016/j.radonc.2022.08.007 10.1016/j.radonc.2022.08.007 PubMedWeb of Science®Google Scholar 18Ababneh HS, Ng AK, Frigault MJ, et al. Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy. Haematologica. 2023; 108(11): 2972-2981. Published online June 15. https://doi.org/10.3324/HAEMATOL.2023.282804 10.3324/haematol.2023.282804 CASPubMedWeb of Science®Google Scholar Volume42, Issue1January 2024e3243 ReferencesRelatedInformation